Applied Therapeutics Inc
NASDAQ:APLT

Watchlist Manager
Applied Therapeutics Inc Logo
Applied Therapeutics Inc
NASDAQ:APLT
Watchlist
Price: 9.625 USD 3.83% Market Closed
Market Cap: 1.1B USD
Have any thoughts about
Applied Therapeutics Inc?
Write Note

Applied Therapeutics Inc
Net Issuance of Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Applied Therapeutics Inc
Net Issuance of Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Debt CAGR 3Y CAGR 5Y CAGR 10Y
Applied Therapeutics Inc
NASDAQ:APLT
Net Issuance of Debt
-$1.9m
CAGR 3-Years
5%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Net Issuance of Debt
$9.3B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Net Issuance of Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Net Issuance of Debt
-$360m
CAGR 3-Years
N/A
CAGR 5-Years
41%
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Issuance of Debt
-$42.5m
CAGR 3-Years
-15%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Issuance of Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Applied Therapeutics Inc
Glance View

Market Cap
1.1B USD
Industry
Biotechnology

Applied Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 34 full-time employees. The company went IPO on 2019-05-09. The Company’s molecular target is aldose reductase (AR), an enzyme that converts glucose to sorbitol under oxidative stress conditions. Its product candidates include AT-007, AT-001, AT-003 and AT-104. The Company’s AT-007 is a central nervous system (CNS) penetrant ARI, which is developed for the treatment of galactosemia. AT-001 is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is developed for the treatment of diabetic cardiomyopathy (DbCM), fatal fibrosis of the heart. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR). AT-104 is a dual selective PI3K inhibitor in preclinical development for T Cell Acute Lymphoblastic Leukemia (T-ALL).

APLT Intrinsic Value
6.71 USD
Overvaluation 30%
Intrinsic Value
Price

See Also

What is Applied Therapeutics Inc's Net Issuance of Debt?
Net Issuance of Debt
-1.9m USD

Based on the financial report for Dec 31, 2023, Applied Therapeutics Inc's Net Issuance of Debt amounts to -1.9m USD.

What is Applied Therapeutics Inc's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 3Y
5%

Over the last year, the Net Issuance of Debt growth was 43%. The average annual Net Issuance of Debt growth rates for Applied Therapeutics Inc have been 5% over the past three years .

Back to Top